Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07805356 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism

Study acronym: RECLAIM-HP
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened
    • Trial sites expanded: 0 → 5 locations
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the study is to evaluate the efficacy, safety, and tolerability of orally administered encaleret tablets in participants with chronic hypoparathyroidism (HP).
Trial Details
NCT Number NCT07805356
Lead Sponsor Calcilytix Therapeutics, Inc., a BridgeBio company
Conditions
(from sponsor)		 Hypoparathyroidism, Chronic Hypoparathyroidism
Related terms Hypoparathyroidism
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov